1. How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study
- Author
-
Vlasis Polychronopoulos, Aliki Venetsanopoulou, Christos F. Kampolis, Panayiotis G. Vlachoyiannopoulos, Athanasios G. Tzioufas, and Foteini Karakontaki
- Subjects
Male ,High-resolution computed tomography ,medicine.medical_specialty ,Vital capacity ,Vital Capacity ,Immunology ,Gastroenterology ,Pulmonary function testing ,03 medical and health sciences ,FEV1/FVC ratio ,0302 clinical medicine ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Lung ,Aged ,Autoantibodies ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Interstitial lung disease ,Autoantibody ,Retrospective cohort study ,Middle Aged ,respiratory system ,Prognosis ,medicine.disease ,Respiratory Function Tests ,respiratory tract diseases ,Survival Rate ,030228 respiratory system ,Disease Progression ,Female ,Lung Diseases, Interstitial ,business - Abstract
Objectives This study aimed to investigate whether positive serum autoantibodies (AAbs) have any impact on survival and time evolution of radiological findings and pulmonary function indices in patients with interstitial lung disease (ILD). Patients and methods Ninety four patients with regular clinical, functional and high resolution computed tomography (HRCT) imaging follow-up for at least 12 consecutive months and complete testing for a panel of AAbs most commonly associated with ILD were enrolled in this retrospective two-center study. Eligible patients were divided into two groups based on the presence [ILD/AAb(+)] (n = 69) or absence [ILD/AAb(−)] (n = 25) of positive serum AAbs. All-cause mortality and longitudinal indicators of ILD progression such as a sustained decrease from baseline in absolute measurements of forced vital capacity (FVC) of ≥10% or single-breath diffusion capacity (DLCOSB) of ≥15% were the primary study endpoints. DLCOSB Results ILD/AAb(+) patients were predominantly female (71% vs 32%), were significantly younger (54.8 ± 14.6 vs 66.8 ± 10.1 years), and had longer duration of follow-up (78.1 ± 53.1 vs 41.6 ± 26.7 months), compared with ILD/AAb(−) patients (p Conclusions AAb(+) patients with ILD seem to have a more favorable prognosis regarding all-cause mortality, long-term deterioration in lung function parameters and progression of HRCT findings than their AAb (−) counterparts.
- Published
- 2018